Niranib 140 MG (Niraparib)

Basic Product Information of Niranib 140 MG (Niraparib)

How Niranib 140 MG (Niraparib) Works: PARP Inhibition Mechanism

Niraparib, the active ingredient in Niranib 140 MG, is a selective inhibitor of PARP-1 and PARP-2. Poly (ADP-ribose) polymerase (PARP) is a family of nuclear enzymes that detect single-strand DNA breaks and recruit the base excision repair machinery to fix them. When a PARP enzyme is blocked, single-strand breaks persist, and each round of cell division converts them into double-strand breaks.

Healthy cells repair double-strand breaks through homologous recombination repair (HRR), a pathway that depends on functional BRCA1 and BRCA2 proteins. Tumors with BRCA1/2 mutations or homologous recombination deficiency (HRD) cannot complete this repair, so PARP inhibition pushes them toward cell death through a concept called synthetic lethality. Niraparib also traps PARP enzymes on DNA, which creates a physical lesion that is more toxic than enzyme inhibition alone. Roughly half of high-grade serous ovarian cancers show HRD, which is why biomarker testing is a central part of ovarian cancer care. Patients and oncologists building a complete treatment plan can review the wider oncology medicines catalogue at Mediaid Pharmacy for supportive and companion therapies.

In the pivotal NOVA trial (recurrent platinum-sensitive ovarian cancer), niraparib maintenance produced a median progression-free survival (PFS) of 21.0 months versus 5.5 months for placebo in the germline BRCA-mutated cohort (hazard ratio 0.27). In the non-germline BRCA HRD-positive cohort, median PFS was 12.9 months versus 3.8 months (hazard ratio 0.38). Niraparib is notable because it delivered PFS benefit across biomarker groups, including patients without BRCA mutations.

Approved Indications of Niraparib (Reference Label for Niranib 140 MG (Niraparib))

Niraparib, the active ingredient in Niranib 140 MG, is approved internationally as maintenance therapy in two adult ovarian cancer settings. Prescribers in Bangladesh should confirm the exact indications on the local Niranib product label.

Key Clinical Benefits of Niranib 140 MG (Niraparib)

How to Take Niranib 140 MG (Niraparib): Dosage Guidelines

Clinical Monitoring Requirements During Niranib 140 MG (Niraparib) Treatment

Regular monitoring is mandatory during niraparib therapy. Hematologic toxicity (thrombocytopenia, anemia, and neutropenia) is the most common serious effect, and the reference label advises a complete blood count weekly during the first month, monthly for the next 11 months, and periodically afterward. Treatment should not start until hematologic toxicity from prior chemotherapy has recovered to grade 1 or better. Thrombocytopenia typically appears early, so the first month is the highest-risk window.

Hypertension, including hypertensive crisis, has been reported. The reference label advises monitoring blood pressure and heart rate at least weekly for the first two months, monthly for the first year, and periodically afterward, with antihypertensive therapy started or adjusted as needed. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in a small percentage of patients, so persistent cytopenias should prompt referral for hematologic evaluation. Posterior reversible encephalopathy syndrome (PRES) is rare, and patients with headache, visual disturbance, confusion, or seizures need urgent assessment.

Drug Interactions and Important Safety Information for Niranib 140 MG (Niraparib)

Niraparib is cleared mainly by carboxylesterases rather than by CYP450 enzymes, so it is not expected to produce major pharmacokinetic interactions with CYP inhibitors or inducers. Even so, patients must give their oncologist a full list of prescription drugs, over-the-counter medicines, and herbal products before starting Niranib 140 MG. Myelosuppressive agents used alongside niraparib can worsen anemia, neutropenia, and thrombocytopenia, and they require closer blood count monitoring.

Anticoagulants and antiplatelet drugs deserve extra attention because niraparib can lower platelet counts and raise bleeding risk. Antihypertensive therapy may need adjustment because niraparib can raise blood pressure. Patients should avoid driving or operating machinery if they experience fatigue, dizziness, or reduced concentration. Female patients of reproductive potential must use effective contraception during treatment and for six months after the final dose, and women must not breastfeed during treatment and for one month after the final dose.

Side Effects and Precautions of Niranib 140 MG (Niraparib)

Who Should Use Niranib 140 MG (Niraparib)?

Niranib 140 MG (Niraparib) is prescribed for adult women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy, in the first-line or recurrent platinum-sensitive setting. Oncologists usually confirm response by imaging and CA-125 trends, and they often order BRCA and HRD testing to guide the maintenance choice, although niraparib has shown benefit regardless of biomarker status. A baseline complete blood count and blood pressure reading are required before the first dose. Niranib 140 MG is prescribed by gynecologic oncologists and medical oncologists experienced with PARP inhibitor therapy. For patients who need broader cancer care across tumor types, Mediaid Pharmacy’s oncology specialty medicines range offers a wide selection of targeted and supportive therapies.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Niranib 140 MG (Niraparib)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Niranib 140 MG (Niraparib) is available in a 120’s capsule pack, and orders are supported by pricing quotations, stock confirmation, documentation, and delivery tracking. Hospitals, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all questions about Niranib 140 MG Niraparib availability, pricing, and international delivery. Buyers who need several cancer medicines in one consignment can browse the full oncology medicine collection before requesting a combined quotation.

Why Choose Niranib 140 MG (Niraparib) from Mediaid Pharmacy?

Niranib 140 MG (Niraparib) gives oncology teams a Bangladesh-registered niraparib capsule for ovarian cancer maintenance therapy, backed by the PARP inhibitor evidence generated in the NOVA and PRIMA trials. Mediaid Pharmacy supplies it in a 120’s pack with clear product specifications, direct specialist support, and worldwide shipping. Every order starts with a prescription-based enquiry, which keeps supply aligned with clinical need. To compare niraparib with other targeted agents or to source additional cancer therapies, visit the Mediaid Pharmacy oncology medicines section, then contact our team for a personalized quotation.

Frequently Asked Questions About Niranib 140 MG (Niraparib)